1. Scrip
  2. >>Business

Six Key Infectious Disease New Drug Launches To Look Out For In 2022

 
• By Alexandra Shimmings

In a series on articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are six new anti-infectives expected to reach the market for the first time next year, all with an above average likelihood of approval.  

3D render bacteria virus,3d render microbe. Bacteria virus or germs microorganism cells under microscope.
• Source: Shutterstock

Seres Therapeutics, Inc. is expected to file for approval of SER-109 in late 2021 or early 2022, paving the way for it to become the first microbiome therapeutic approved for the prevention of Clostridioides difficile.

In early July, the US firm signed a lucrative deal with Nestle Health Science to jointly commercialize SER-109 in North America for recurrent C difficile infection (it already had rights outside of the US and Canada)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.